EXHIBIT 99.1
Contact:
Christopher J. Geberth Carney Duntsch
Vice President Finance Investor Relations
Diomed Holdings, Inc. Burns McClellan
(877) 434-6633 or (978) 824-1816 (212) 213-0006
investor-relations@diomedinc.com cduntsch@burnsmc.com
DIOMED ANNOUNCES THIRD QUARTER RESULTS
Company Delivers 22% Increase in EVLT(R) Sales
ANDOVER, MA, October 26, 2006 --- Diomed Holdings, Inc. (AMEX: DIO), a leading
developer and marketer of minimally invasive medical technologies, including its
patented EVLT(R) laser treatment for varicose veins, today announced results for
the third quarter ended September 30, 2006.
Significant accomplishments during the third quarter of 2006 included:
o Diomed's third highest quarterly revenue performance, at $5.3
million;
o EVLT(R) revenue, 22% above the third quarter of 2005;
o EVLT(R) disposable revenue, 44% over the third quarter of 2005;
o EVLT(R) installed base exceeds 1,000 laser systems;
o Nearly 80,000 EVLT(R) procedures successfully performed;
o Close of $10 million preferred stock financing, increasing cash and
short term investments to $13.4 million.
o Summary Judgment ruling that `777 patent is valid and enforceable,
eliminating two of the three defenses and allowing trial on
infringement action to proceed;
"We are pleased with our third quarter accomplishments," commented James A.
Wylie, CEO and President of Diomed Holdings, Inc. "The Company drove significant
year-over-year growth in what is traditionally our softest quarter due to
seasonality in our key North American EVLT(R) market. Additionally, Diomed
delivered revenue for the nine months ended September 30, 2006 of $16 million,
an increase of $2.5 million, or 18%, over the first nine months of 2005, while
EVLT(R) sales increased a solid 23%."
"Of particular note is our continued growth in laser market share. During the
three-month period ending August 2006, Diomed sold over three times the number
of lasers sold by our largest competitor, strengthening our belief that Diomed's
installed base exceeds the installed base of all of our laser competitors
combined." Wylie further commented.
Gross profit for the third quarter of 2006 was $2.3 million, representing an
increase of $208,000, or 10%, over the third quarter of 2005. Gross profit as a
percentage of sales of 43% decreased 2.4 percentage points against the third
quarter of 2005, as a less favorable product mix and lower overhead absorption
offset favorable pricing variances. The Company has targeted continued
improvement in gross profit levels to the 60% level and higher, consistent with
other proprietary medical device companies, as the EVLT(R) product line grows.
4
Selling and marketing expenses for the third quarter of 2006 were $2.7 million,
an increase of $606,000, or 29%, over the third quarter of 2005. The increase
was driven by an expansion of our sales force, higher sales commissions
resulting from the increased sales volume and increased marketing expenditures
in support of our sales initiatives to drive the growing commercialization of
EVLT(R). For the nine months ended September 30, 2006, selling and marketing
expenses were $8.5 million, an increase of $1.8 million, or 27%, over the same
period of 2005.
General and administrative expenses for the third quarter of 2006 of $1.9
million increased $95,000, or 5%, compared to the third quarter of 2005, and
were relatively flat sequentially. Total third quarter legal costs of $694,000
decreased $16,000 from the second quarter of 2006, with a reduction in the
continuing cost of litigation against our primary laser competitors offset by
the cost of litigation in the action brought by our radio-frequency competitor.
For the nine months ended September 30, 2006, general and administrative
expenses were $5.9 million, an increase of $390,000, or 7%, over the same period
in 2005.
Losses from operations for the third quarter of 2006 of approximately $2.7
million increased $513,000 from the third quarter of 2005, as gains from
incremental revenue were offset by increased selling and marketing costs and
$126,000 in SFAS 123R compensation costs. Losses from operations for the nine
months ended September 30, 2006 were $8.3 million, compared with $7.2 million
for the same period in 2005, and included $444,000 in SFAS 123R stock based
compensation charges.
Net loss for the third quarter of 2006 of $3.0 million increased by $620,000, or
26%, from the third quarter of 2005. Net loss for the third quarter of 2006
includes a $69,000 non-cash, non-operating loss for the increase in the fair
value of the warrant obligation entered into on September 30, 2005, as the
market price of the Company's stock increased from $1.11 at June 30, 2006 to
$1.20 at September 30, 2006. As a result of the financing which closed on
September 29, 2006, the Company marked to market the warrant obligation for a
final time and reclassified its mezzanine level preferred stock and warrant
liability to permanent equity.
Upon completion of the 2006 preferred stock financing, the Company recorded a
one-time, non-cash, non-operating beneficial conversion feature charge of
$469,938, since the market price of the Company's common stock on September 29,
2006 of $1.20 was above the $1.15 effective conversion price of the immediately
convertible preferred stock. The Company also recorded a one-time, non-cash,
non-operating deemed dividend of $3.0 million on the exchange of the 2005
preferred stock for the 2006 preferred stock.
Net loss applicable to common stockholders for the third quarter of 2006 was
$6.7 million, or $0.35 per share, compared to $3.1 million, or $0.16 per share,
for the third quarter of 2005. Net loss applicable to common stockholders for
the third quarter of 2006 includes $167,000 of non-cash preferred stock
dividends accreted for future increasing rate dividends and $149,000 of
preferred stock cash dividends earned during the third quarter on the 2005
preferred stock. As noted above, the 2005 preferred stock was exchanged for the
2006 preferred stock under the 2006 financing, which does not accrue dividends
unless a future dilutive financing is completed within certain terms.
5
The Company ended the third quarter of 2006 with a cash and short term
investment balance of $13.4 million, compared to a cash and short term
investment balance of $7.0 million at the end of the second quarter of 2006. The
cash balance includes approximately, $9.3 million in net proceeds received from
the 2006 preferred stock financing.
Conference Call Information
Diomed will hold a conference call to review its third quarter 2006 financial
results on Thursday, October 26, 2006, at 10:00 a.m. (ET). The call will be
hosted by James A. Wylie, Jr., President and Chief Executive Officer, and David
B. Swank, Chief Financial Officer.
Interested parties may access the conference call by dialing 866-831-6162
(domestic) or 617-213-8852 (international), participant pass code 146644724. The
call will also be available via web cast at www.diomedinc.com.
If you are unable to participate, an audio digital replay of the call will be
available from Thursday, October 26, 2006, 12:00 p.m. ET, until Thursday,
November 2, 2006, 12:00 p.m. ET. The digital replay can be accessed by dialing
1-888-286-8010, (domestic) or 1-617-801-6888 - (international), using pass code
92289158. A web archive will also be available during this time period at
www.diomedinc.com.
About Diomed
Diomed develops and commercializes minimal and micro-invasive medical procedures
that use its proprietary laser technologies and disposable products. Diomed's
EVLT(R) laser vein ablation procedure is used in varicose vein treatments.
Diomed also provides photodynamic therapy (PDT) for use in cancer treatments,
and dental and general surgical applications. The EVLT(R) procedure and the
Company's related products were cleared by the United States FDA in January of
2002. Along with lasers and single-use procedure kits for its EVLT(R) laser vein
treatment, the Company provides its customers with state of the art physician
training and practice development support. Additional information is available
on the Company's website: www.evlt.com.
EVLT(R) is a registered trademark of Diomed Inc., Andover, MA.
6
Safe Harbor
Safe Harbor statements under the Private Securities Litigation Reform Act of
1995: Statements in this news release looking forward in time involve risks and
uncertainties, including the risks associated with trends in the products
markets, reliance on third party distributors in various countries outside the
United States, reoccurring orders under OEM contracts, market acceptance risks,
technical development risks and other risk factors. These statements relate to
our future plans, objectives, expectations and intentions. These statements may
be identified by the use of words such as "may," "will," "should," "potential,"
"expects," "anticipates," "intends," "plans," "believes" and similar
expressions. These statements are based on our current beliefs, expectations and
assumptions and are subject to a number of risks and uncertainties. Our actual
results could differ materially from those discussed in these statements. Our
Annual Report on Form SEC 10-KSB/A (the "Annual Report") contains a discussion
of certain of the risks and uncertainties that affect our business. We refer you
to the "Risk Factors" on pages 23 through 38 of the Annual Report for a
discussion of certain risks, including those relating to our business as a
medical device company without a significant operating record and with operating
losses, our risks relating to our commercialization of our current and future
products and applications and risks relating to our common stock and its market
value. Diomed disclaims any obligation or duty to update or correct any of its
forward-looking statements.
7
Diomed Holdings, Inc.
(Unaudited) Condensed Consolidated Statements of Operations
Three Months and Nine Months Ended September 30, 2006 and 2005
Three Months Three Months Nine Months Nine Months
Ended Ended Ended Ended
September 30, September 30, September 30, September 30,
2006 2005 2006 2005
------------- ------------- ------------- -------------
Revenues $ 5,321,080 $ 4,582,840 $ 15,972,476 $ 13,488,120
Cost of revenues 3,042,223 2,511,536 8,786,487 7,325,127
------------ ------------ ------------ ------------
Gross profit 2,278,857 2,071,304 7,185,989 6,162,993
------------ ------------ ------------ ------------
Operating expenses:
Research and development 422,596 403,498 1,140,170 1,150,712
Selling and marketing 2,687,000 2,080,723 8,490,263 6,693,660
General and administrative 1,906,886 1,811,921 5,865,439 5,475,535
------------ ------------ ------------ ------------
Total operating expenses 5,016,482 4,296,142 15,495,872 13,319,907
------------ ------------ ------------ ------------
Loss from operations (2,737,625) (2,224,838) (8,309,883) (7,156,914)
------------ ------------ ------------ ------------
Other (income) expense
(Gain) Loss on fair value adjustment on
warrant liability 68,995 -- (971,442) --
Interest expense, non-cash 96,078 98,904 288,229 1,502,760
Interest expense, net and other (income) 76,480 35,405 (958) 187,773
------------ ------------ ------------ ------------
Total other (income) expense, net 241,553 134,309 (684,171) 1,690,533
------------ ------------ ------------ ------------
Net loss (2,979,178) (2,359,147) (7,625,712) (8,847,447)
Less preferred stock cash dividends (149,063) -- (447,353) --
Less preferred stock non-cash dividends (167,480) (762,656) (483,586) (762,656)
Less beneficial conversion feature on
2006 preferred stock (469,938) -- (469,938) --
Less deemed dividend on the exchange of
2005 preferred stock (2,980,439) -- (2,980,439) --
------------ ------------ ------------ ------------
Net loss applicable to common stockholders $ (6,746,098) $ (3,121,803) $(12,007,028) $ (9,610,103)
============ ============ ============ ============
Basic and diluted net loss per share
applicable to common stockholders $ (0.35) $ (0.16) $ (0.62) $ (0.50)
============ ============ ============ ============
Basic and diluted weighted average
common shares outstanding 19,448,728 19,423,728 19,447,812 19,143,276
============ ============ ============ ============
8
Diomed Holdings, Inc.
Condensed Consolidated Balance Sheets
As of September 30, 2006 (unaudited) and December 31, 2005
ASSETS September 30, 2006 December 31, 2005
------------------ -----------------
Current assets:
Cash and cash equivalents $12,941,840 $ 9,562,087
Short term investments 498,595 3,566,454
Accounts receivable, net 2,629,923 2,824,717
Inventories 3,874,721 3,059,886
Prepaid expenses and other current assets 713,820 444,453
----------- -----------
Total current assets 20,658,899 19,457,597
Property, plant and equipment, net 1,272,790 1,171,703
Intangible assets, net 4,125,294 4,302,915
Investment 1,000,000 500,000
Other assets 229,014 294,810
----------- -----------
Total assets $27,285,997 $25,727,025
=========== ===========
LIABILITIES, PREFERRED STOCK AND
STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 4,180,333 $ 3,561,786
Accrued expenses 2,104,597 2,298,823
Current portion of deferred revenue 260,625 257,889
Bank loan 420,519 53,924
Current maturities of capital lease obligations 1,389 2,047
EVLT technology payable (zero face value at
September 30, 2006 and $250,000 face
value, net of $4,902 debt discount at
December 31, 2005) -- 245,098
Warrant liability -- 1,898,213
----------- -----------
Total current liabilities 6,967,463 8,317,780
Deferred revenue, net of current portion 108,527 144,428
Capital lease obligation, net of current maturities 2,778 4,094
Convertible notes payable ($3,712,000 face value,
net of $3,712,000 debt discount at
September 30, 2006 and $3,712,000 face value,
net of $1,081,727 debt discount at
December 31, 2005) -- 2,630,273
----------- -----------
Total liabilities 7,078,768 11,096,575
Preferred Stock -- 7,819,658
Stockholders' equity 20,207,229 6,810,792
----------- -----------
Total liabilities, preferred stock and stockholders' equity $27,285,997 $25,727,025
=========== ===========
9